deltatrials
Terminated PHASE2 NCT00003491

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Lung

Sponsor: Burzynski Research Institute

Conditions Stage IV Lung Cancer
Interventions Antineoplaston therapy (Atengenal + Astugenal)
Updated 7 times since 2017 Last updated: Sep 27, 2017 Started: Mar 20, 1996 Primary completion: Jul 31, 1998 Completion: Jul 31, 1998

Listed as NCT00003491, this PHASE2 trial focuses on Stage IV Lung Cancer and remains terminated or withdrawn. Sponsored by Burzynski Research Institute, it has been updated 7 times since 1996, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Oct 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Sep 2017 — Oct 2017 [monthly]

    Terminated PHASE2

    Status: Unknown Status → Terminated

  2. Jan 2017 — Sep 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Mar 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Burzynski Research Institute
Data source: Burzynski Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States